FDA 483 - Dr. Reddy's Laboratories Limited (Unit II) - November 19, 2024

The FDA issued a Form 483 to Dr. Reddy's Laboratories Limited (Unit II), an API manufacturer in Hyderabad, Telangana, India, following an inspection conducted from November 13 to November 19, 2024. The inspection revealed significant deviations from Current Good Manufacturing Practices (cGMP), indicating a lack of robust quality control and process management. Key issues included a recurring problem with inadequate investigations into product complaints, failing to identify root causes or implement effective corrective actions for issues like out-of-specification particle size distribution. The firm also demonstrated a failure to maintain manufacturing processes in a validated state, evidenced by numerous out-of-specification results for water content and product yield without effective preventive measures. Observations also highlighted deficiencies in the quality control unit, specifically regarding inconsistent change control assessments and personnel hygiene practices. Equipment and facility integrity were compromised, with concerns about computer system controls, lack of adequate cleaning validation for recovered solvents and scaled-up processes, visible contamination, and poor facility maintenance (e.g., lack of hot water, insect presence, dirty vents). Furthermore, laboratory controls were found to be lacking, including insufficient stability testing after process changes, improper labeling and packaging of stability samples, use of expired calibration standards, and a failure to ensure the quality of incoming bulk water without proper documentation or testing. The FDA requires Dr. Reddy's Laboratories to address these observations by implementing comprehensive corrective and preventive actions to ensure compliance with cGMP regulations and prevent recurrence of these deficiencies.